Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases.Valproic acid kicker pro comp 10 (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor.The aim of this research was to determine the anti-leukemic effects of dasatin